What Ongoing Monitoring for Tysabri Patients Involves

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

Understanding Treatment Risks in Context

If you or a loved one is taking Tysabri, you may wonder what ongoing monitoring looks like and why it matters. The medical community has long recognized that balancing treatment benefits with safety requires careful, routine evaluation. This page explains the testing and evaluation process used to detect PML early and manage risk.

Clinical Evidence and Risk Factors for PML After Tysabri

Tysabri (natalizumab) is a biologic therapy approved for the treatment of multiple sclerosis and Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. The long-term prognosis for patients who develop PML after Tysabri exposure is generally poor, with the condition "usually lead[ing] to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML is an opportunistic viral infection of the brain caused by the JC virus (JCV) that typically occurs only in immunocompromised individuals (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). In Tysabri-treated patients, the infection arises because the drug alters immune surveillance in the central nervous system. Tysabri is a monoclonal antibody that binds to alpha-4 integrins, preventing lymphocyte migration across the blood-brain barrier. This mechanism reduces inflammation in multiple sclerosis but also impairs the brain's ability to control latent JCV infection, allowing viral reactivation and lytic infection of oligodendrocytes. The resulting demyelination leads to progressive neurological deficits. Clinical presentation of PML can be subtle and may mimic multiple sclerosis relapses. Symptoms include progressive weakness, visual disturbances, cognitive decline, and coordination problems. Because of this overlap, the prescribing information emphasizes that "an MRI scan should be obtained prior to initiating therapy with TYSABRI" to help differentiate subsequent multiple sclerosis symptoms from PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). For Crohn's disease patients, a baseline brain MRI may also be helpful, though brain lesions at baseline are uncommon (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Diagnosis typically requires MRI findings of multifocal white matter lesions, detection of JCV DNA in cerebrospinal fluid, and exclusion of other causes. Three risk factors for PML in Tysabri-treated patients have been identified: "the presence of anti-JCV antibodies, duration of therapy, and prior use of immunosuppressants" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk, and longer treatment duration—especially beyond two years—further increases risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Prior immunosuppressant use compounds this risk. These factors should be weighed against expected benefit when initiating and continuing treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Prognosis and Long-Term Outcomes

The timeline between Tysabri exposure and documented harm varies. In clinical trials, PML occurred in three patients: two with multiple sclerosis treated for a median of 120 weeks (who also received interferon beta-1a), and one with Crohn's disease after eight doses (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Importantly, PML has been reported following discontinuation of Tysabri in patients who did not have findings suggestive of PML at the time of discontinuation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This indicates that the infection can become clinically apparent after therapy ends, necessitating continued monitoring for at least six months after stopping Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Prognosis for PML after Tysabri is guarded. The boxed warning states that PML "usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, outcomes can vary depending on the extent of brain involvement, immune status, and timing of intervention. Early detection and prompt withdrawal of Tysabri may improve prognosis, but even with treatment, many patients experience permanent neurological deficits. The prescribing information mandates that "TYSABRI dosing should be withheld immediately at the first sign or symptom suggestive of PML" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Additionally, because of the risk of PML, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Adequacy of warnings regarding Tysabri and PML is addressed through the boxed warning, which clearly states the risk and identifies known risk factors. The prescribing information also provides guidance on monitoring and management. However, the occurrence of PML after discontinuation underscores the need for vigilance even after therapy ends. For affected patients, prognosis-related considerations include the potential for severe disability or death, the importance of early detection, and the need for long-term monitoring. In summary, PML is a serious adverse effect of Tysabri with a poor long-term prognosis. Risk is increased by anti-JCV antibodies, longer treatment duration, and prior immunosuppressant use. The infection can occur during therapy or after discontinuation, and early recognition is critical. The prescribing information provides clear warnings and monitoring recommendations, but the condition remains life-threatening.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the long-term prognosis for PML after Tysabri?

The long-term prognosis for PML after Tysabri is generally poor, with the condition usually leading to death or severe disability, according to the prescribing information (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, outcomes vary depending on early detection, immune status, and intervention timing.

Can PML occur after stopping Tysabri?

Yes, PML has been reported following discontinuation of Tysabri in patients who did not have findings suggestive of PML at the time of discontinuation. Continued monitoring for at least six months after stopping Tysabri is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Tysabri Prescribing Information (DailyMed)

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.